The global Community Acquired Bacterial Pneumonia (CABP) Treatment Market is worth US$ 5 Billion as of now and is expected to reach US$ 8.38 Billion by the year 2033 at a CAGR of 5.3% between 2023 and 2033.
Community acquired bacterial pneumonia (CABP) is a kind of pneumonia acquired outside of healthcare setting or hospital through bacteria like haemophilus influenza, streptococcus pneumonia, and legionella pneumophila.
CABP’s cases are rising worldwide due to COPD (chronic obstructive pulmonary disease), smoking, and geriatric population. Research states that incidences of community acquired pneumonia does vary from 1.5 to 14 cases per person-years. This could be attributed to respective season, geography, and population. Plus, close to 650 adults get hospitalized due to community acquired bacterial pneumonia per 100K population every single year.
Get Sample PDF: https://www.futuremarketinsights.com/reports/sample/rep-gb-16837
At the same time, the fact that the initial cost of treating community acquired bacterial pneumonia is higher can’t be ignored. This factor is expected to restrain the community acquired bacterial pneumonia treatment market in the forecast period.
Future Market Insights has walked through these facts with future prospects in its latest market study entitled ‘Community Acquired Bacterial Pneumonia Treatment Market’. It has its team of analysts and consultants to check through the nitty-gritties all across.
“With growing awareness about need to mitigate community acquired bacterial pneumonia, the global community acquired bacterial pneumonia treatment market is likely to grow on an astute note in the forecast period”, says an analyst from Future Market Insights.
Key Takeaways from Community Acquired Bacterial Pneumonia Treatment Market
- Southern and Eastern Asia are the hotspots for community acquired bacterial pneumonia. As such, the Asia-Pacific is expected to grow on a stupendous note in the community acquired bacterial pneumonia treatment market. India and China lead from the front.
- North America holds a sizable market share with the US being at the forefront herein. This could be attributed to the region being home to well-trained healthcare personnel.
- Europe is expected to go steady on the count of community acquired bacterial pneumonia treatment market with the regions like the UK making relentless efforts to curb community acquired bacterial pneumonia.
Contact Us for a Discount: https://www.futuremarketinsights.com/request-discount/rep-gb-16837
Competitive Analysis
- The US FDA, of late, did grant approval for lefamulin (Xenleta) for treating adults contracting community acquired bacterial pneumonia. This drug renders extra treatment option for those suffering from serious illness; which could vary in severity (from mild to severe) and affect those belonging to all the ages.
- The key players in community acquired bacterial pneumonia treatment market include Paratek Pharmaceuticals, Inc., Nabriva Therapeutics, Allergan plc, Melinta Therapeutics, Inc., Lupin Pharmaceuticals, Takeda Pharmaceutical Company Ltd., dainippon Sumitomo Pharma, Pfizer Inc., Mylan N.V., Bayer AG, Basilea Pharmaceutica International AG, and likewise.
What does the Report state?
- The research study is based on form of dose (solution and tablet), by drug class (pleuromutilin, cephalosporin, glycylcycline, oxazolidinone, and ketolide), by route of administration (oral and intravenous), and by distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy).
- Growing frequency of community acquired pneumonia is expected to drive the community acquired bacterial pneumonia treatment market in the forecast period.
Customize Your Report Now: https://www.futuremarketinsights.com/customization-available/rep-gb-16837
Key Segments Profiled in the Community Acquired Bacterial Pneumonia (CABP) Treatment Industry Survey
Dose Form:
- Solution
- Tablet
Drug Class:
- Pleuromutilin
- Cephalosporin
- Glycylcycline
- Oxazolidinone
- Ketolide
Route of Administration:
- Oral
- Intravenous
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
